EXPO vs FCN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: FCN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. EXPO and FCN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined EXPO and FCN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Exponent, Inc. is a Menlo Park, California engineering and scientific consulting firm founded in 1967 that solves complex technical problems for corporations, law firms, insurers, and government agencies. Its two segments are Engineering and Other Scientific (roughly 85% of net revenues), covering failure analysis, product testing, user research, and disputes across consumer electronics, energy, utilities, transportation, and life sciences, and Environmental and Health (about 15%). The business is people-based rather than asset-based, so its economics revolve around billable hours, staff utilization, and realized billing rates, and its brand as a science-for-hire authority lets it command premium fees on reactive, high-stakes engagements.

Full EXPO guide

FTI Consulting is a global expert firm that advises corporations, law firms, governments, and financial institutions through five segments: Corporate Finance and Restructuring (its largest, roughly 41% of revenue), Forensic and Litigation Consulting (~20%), Economic Consulting (~19%), Technology (~10%), and Strategic Communications (~10%). Its work spans turnaround and restructuring, transactions, disputes and investigations, antitrust and regulatory economics, e-discovery, and corporate reputation. The firm employs roughly 8,100 people, of whom about 6,400 are billable professionals, and generates around 63% of revenue from US-based professionals.

Full FCN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• EXPO drivers: Reactive and disputes demand; AI-enabled products and new risk categories.
• FCN drivers: Restructuring and Corporate Finance strength; Record Strategic Communications demand.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Exponent's output is entirely dependent on attracting and retaining specialized PhD-level and engineering talent, so wage inflation, attrition, or hiring shortfalls directly pressure capacity and margins. For FCN, the Economic Consulting segment has been a clear drag, with revenue declining and swinging to a segment EBITDA loss on softer antitrust and economic-analysis demand plus elevated compensation; the October 2026 leadership change at Compass Lexecon is an attempt to reset that unit.

Pick EXPO if you believe its drivers more; FCN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the EXPO and FCN guides.

EXPO. Exponent's Q1 2026 revenue rose about 14% to roughly $166 million with net income up 11% to about $30 million, aided by 76% utilization and roughly 399,000 billable hours, and Q2 2026 extended the run with revenue up about 12% and EPS of $0.60, in line with estimates. At about $71.85 in mid-October 2026 the shares trade near 32x trailing and 26x forward earnings, a rich multiple for a firm growing in the low teens, which is the market's view of the franchise as a durable, high-quality compounder. Analysts expect about $2.41 of EPS for 2026 and $2.72 for 2027, and Q3 results land on October 29.

FCN. FCN closed near $145.85 on October 16, 2026, within a 52-week range of roughly $129 to $189, down about 14% year to date. Its trailing P/E near 17.6x falls to about 13.4x on forward estimates, a discount that reflects margin worries and two straight EPS misses even as revenue keeps growing. Q3 2026 results are due October 29, with consensus near $2.74 per share on about $1.01 billion of revenue.

Headline figures (approximate, October 2026): EXPO shows revenue (ttm) ~$567M, q2 2026 revenue ~$149M (+~12% YoY), q2 2026 eps (diluted) ~$0.60 (in line with consensus), net income (ttm) ~$112M (net margin ~20%); FCN shows revenue (ttm) ~$3.92B (Q2 2026 up ~5.3% YoY), revenue (q2 2026) ~$993M, net income (ttm) ~$253M (profit margin ~6.4%), eps (q2 2026 vs estimate) ~$1.99 vs ~$2.26.

EXPO and FCN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined EXPO and FCN exposure against your real portfolio. It is not an investment adviser.